Clinical trial
Rasburicase Versus Allopurinol in Tumor Patients at Risk for Hyperuricemia and…
NCT00230178 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00230178 |
|---|---|
| Title | Rasburicase Versus Allopurinol in Tumor Patients at Risk for Hyperuricemia and Tumor Lysis Syndrome |
| Official title | Evaluation of Single Agent Rasburicase for 5 Days Versus Sequential Treatment With Rasburicase From Day 1 Through 3 Followed by Oral Allopurinol From Day 3 Through 5 (Overlap on Day 3) Versus Single Agent Oral Allopurinol for 5 Days in the Management of Plasma Uric Acid in Adult Patients With… |
| Lead sponsor | Sanofi, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Tumor Lysis Syndrome, Cancer, Hyperuricemia |
| Intervention type | Drug |
| Interventions | Rasburicase (SR29142), Allopurinol |
| Enrollment | 280 |
| Start date | Apr 1, 2004 |
| Primary completion | Dec 1, 2007 |
| Completion | Dec 1, 2007 |
| First posted | Sep 30, 2005 |
| Last update posted | Jan 12, 2010 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: